User profiles for R. J. Price
RJ PriceNancy and Neal Wade Professor of Biomedical Engineering Verified email at virginia.edu Cited by 6129 |
Golf science research at the beginning of the twenty-first century
…, DJ Crews, MJ Hurdzan, RJ Price… - Journal of sports …, 2003 - Taylor & Francis
At the beginning of the twenty-first century, there are 30,000 golf courses and 55 million
people who play golf worldwide. In the USA alone, the value of golf club memberships sold in …
people who play golf worldwide. In the USA alone, the value of golf club memberships sold in …
[HTML][HTML] Mitochondrial dysfunction in neurological disorders: Exploring mitochondrial transplantation
Mitochondria are fundamental for metabolic homeostasis in all multicellular eukaryotes. In
the nervous system, mitochondria-generated adenosine triphosphate (ATP) is required to …
the nervous system, mitochondria-generated adenosine triphosphate (ATP) is required to …
Drug and gene delivery across the blood–brain barrier with focused ultrasound
The blood–brain barrier (BBB) remains one of the most significant limitations to treatments
of central nervous system (CNS) disorders including brain tumors, neurodegenerative …
of central nervous system (CNS) disorders including brain tumors, neurodegenerative …
[HTML][HTML] K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
…, JD Shapiro, S Robitaille, TJ Price… - … England Journal of …, 2008 - Mass Medical Soc
Background Treatment with cetuximab, a monoclonal antibody directed against the epidermal
growth factor receptor, improves overall and progression-free survival and preserves the …
growth factor receptor, improves overall and progression-free survival and preserves the …
The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity
KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling
protein in tumours 1 , 2 . The KRAS(G12C) mutant has a cysteine residue that has been …
protein in tumours 1 , 2 . The KRAS(G12C) mutant has a cysteine residue that has been …
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may
identify patients at the highest risk of recurrence and help inform adjuvant treatment decisions. …
identify patients at the highest risk of recurrence and help inform adjuvant treatment decisions. …
[HTML][HTML] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
…, GI Shapiro, GS Falchook, TJ Price… - … England Journal of …, 2020 - Mass Medical Soc
Background No therapies for targeting KRAS mutations in cancer have been approved. The
KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to …
KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to …
Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue
Background—Our aim was to observe ultrasound-induced intravascular microbubble
destruction in vivo and to characterize any resultant bioeffects. Methods and Results—Intravital …
destruction in vivo and to characterize any resultant bioeffects. Methods and Results—Intravital …
The Football Association medical research programme: an audit of injuries in academy youth football
RJ Price, RD Hawkins, MA Hulse… - British journal of sports …, 2004 - bjsm.bmj.com
Objectives: To undertake a prospective epidemiological study of the injuries sustained in
English youth academy football over two competitive seasons. Methods: Player injuries were …
English youth academy football over two competitive seasons. Methods: Player injuries were …
[PDF][PDF] Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group …
…, YJ Chua, JR Zalcberg, RJ Simes, TJ Price - 2010 - academia.edu
Purpose To determine whether adding bevacizumab, with or without mitomycin, to
capecitabine monotherapy improves progression-free survival (PFS) in patients with …
capecitabine monotherapy improves progression-free survival (PFS) in patients with …